A bill to amend the Federal Food, Drug and Cosmetic Act to allow increased inspection of records.

[AI summary unavailable — showing source text] Amends the Federal Food, Drug, and Cosmetic Act to extend the inspection authority of the Food and Drug Administration (FDA) over records ( currently limited to manufacturers and distributors of prescription drugs) to manufacturers and distributors of drugs containing caffeine and ephedrine. Permits the Secretary of Health and Human Services to add additional substances to this list, through notice and comment rulemaking, if they become substances of abuse. Prohibits the manufacture and distribution of drugs which a reasonable person would believe to be a controlled substance. Repeals the prohibition on obtaining injunctions against the manufacturers and distributors of counterfeit drugs and the making, selling or concealing of the equipment used to make counterfeit drugs. Extends the FDA's seizure authority to prohibited look-alike drugs.…